---
title: "Lantern Pharma Inc. (LTRN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LTRN.US.md"
symbol: "LTRN.US"
name: "Lantern Pharma Inc."
industry: "Biotechnology"
datetime: "2026-05-19T10:57:55.502Z"
locales:
  - [en](https://longbridge.com/en/quote/LTRN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LTRN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LTRN.US.md)
---

# Lantern Pharma Inc. (LTRN.US)

## Company Overview

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.lanternpharma.com](https://www.lanternpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.12 | 258 | - | - | - |
| PB | 9.80 | 388 | 3.92 | 3.43 | 2.56 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.00 |
| Highest Target | 25.00 |
| Lowest Target | 15.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LTRN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LTRN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LTRN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LTRN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**